Drug
Temodar (Temozolomide)
Temodar (Temozolomide) is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/2)
Active Trials
1(25%)
Terminated
2(50%)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Terminated(2)
Other(1)
Detailed Status
Terminated2
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
terminated250%
unknown125%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_2
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
NCT06805305
terminatedphase_1
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
NCT01067066
terminatedphase_1
Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM
NCT00508456
unknownphase_1
Abraxane and Temodar Plus Genasense in Advanced Melanoma
NCT00409383
Clinical Trials (4)
Showing 4 of 4 trials
NCT06805305Phase 2
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
NCT01067066Phase 1
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
NCT00508456Phase 1
Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM
NCT00409383Phase 1
Abraxane and Temodar Plus Genasense in Advanced Melanoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4